NTLA5001, a T Cell Product Candidate with CRISPR-Based Targeted Insertion of a High-Avidity, Natural, WT1-Specific TCR, Shows Efficacy in In Vivo Models of AML and ALL

Eliana Ruggiero(Vita-Salute San Raffaele University), Birgit C. Schultes(Intellia Therapeutics (United States)), Fabio Ciceri(Vita-Salute San Raffaele University), Simo M Arredouani(Intellia Therapeutics (United States)), Laura Sepp‐Lorenzino(Intellia Therapeutics (United States)), Amy M. Becker(Intellia Therapeutics (United States)), Aaron Prodeus(Intellia Therapeutics (United States)), Ivy Dutta(Intellia Therapeutics (United States)), Qingzhan Zhang(University of Illinois Urbana-Champaign), Chiara Bonini(Vita-Salute San Raffaele University), Mark D. McKee(University of Auckland), Maxwell Gabriel Foisey(Intellia Therapeutics (United States)), Dai Liu(Intellia Therapeutics (United States)), Ishina Balwani(Intellia Therapeutics (United States))

Blood

November 4, 2020

Cited by 1

|Science|2020|2.9k

|New England Journal of Medicine|2021|1.7k

|New England Journal of Medicine|2013|1.6k

|New England Journal of Medicine|2019|1.3k

|New England Journal of Medicine|2009|1k

NTLA5001, a T Cell Product Candidate with CRISPR-Based Targeted Insertion of a High-Avidity, Natural, WT1-Specific TCR, Shows Efficacy in <i>In Vivo</i> Models of AML and ALL